Search Results - "Fay, Andre Poisl"

Refine Results
  1. 1
  2. 2
  3. 3

    Core Needle Biopsy Accuracy for Androgen Receptor Expression in Invasive Breast Cancer by Santos, Marcelle Morais dos, Frasson, Antonio Luiz, Silva, Vinicius Duval da, Maciel, Aluísio de Castro Antunes, Watte, Guilherme, Werutsky, Gustavo, Reinert, Tomás, Fay, André Poisl

    “…Objective Breast cancer (BC) biomarkers, such as hormone receptors expression, are crucial to guide therapy in BC patients. Antiandrogens have been studied in…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Rapid and low-cost liquid biopsy with ATR-FTIR spectroscopy to discriminate the molecular subtypes of breast cancer by Pereira de Souza, Nikolas Mateus, Machado, Brenda Hunter, Padoin, Licerio Vicente, Prá, Daniel, Fay, André Poisl, Corbellini, Valeriano Antonio, Rieger, Alexandre

    Published in Talanta (Oxford) (01-03-2023)
    “…Breast cancer (BC) is the most prevalent cancer worldwide. The prognosis and survival of these patients are directly related to the diagnostic stage. Even so,…”
    Get full text
    Journal Article
  6. 6
  7. 7

    The impact of preoperative immune checkpoint inhibitors on kidney and bladder cancer surgeries: a systematic review by Petzold, Aline Petracco, Lubianca, Fernanda Nascimento, Passos, Laura Gazal, Keppler, Carolina Knorst, Becker, Nicole Bernd, Viera, Carolina de Mello, Fay, André Poisl, Carvalhal, Gustavo Franco

    Published in Current problems in cancer (01-02-2022)
    “…Therapies based on the use of immune checkpoint inhibitors (ICIs), such as nivolumab, pembrolizumab, ipilimumab, atezolizumab, avelumab, and durvalumab, have…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Impact of geographic region on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database by Fay, Andre Poisl, McKay, Rana R., Lin, Xun, Simantov, Ronit, Choueiri, Toni K.

    Published in Journal of clinical oncology (20-05-2017)
    “…Abstract only 4583 Background: Health determinants vary according to the geographic region and may impact the outcomes of mRCC patients treated on clinical…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Impact of primary tumor resection in oligometastatic non-small cell lung cancer: Experience of a resource-limited cancer center in southern Brazil by Nunes Filho, Paulo Ricardo Santos, da Silva, Caroline Albuquerque Moreira, Tsukazan, Maria Teresa Ruiz, Fay, Andre Poisl, Barrios, Carlos H., Debiasi, Marcio

    Published in Journal of clinical oncology (20-05-2017)
    “…Abstract only e20552 Background: Stage IV non-small cell lung cancer (NSCLC) with low volume disease represents a more indolent phenotype within the biological…”
    Get full text
    Journal Article
  15. 15

    ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinium-based chemotherapy: A systematic review and meta-analysis by Urun, Yuksel, Leow, Jeffrey J., Fay, Andre Poisl, Albiges, Laurence, Choueiri, Toni K., Bellmunt, Joaquim

    Published in Journal of clinical oncology (01-03-2015)
    “…Abstract only 351 Background: Platinium based chemotherapy (CT) is an essential part in the treatment of advanced urothelial cancer (AUC). However, not all…”
    Get full text
    Journal Article
  16. 16

    Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials by Moreira, Raphael Brandao, Debiasi, Marcio, Maluf, Fernando C., Bellmunt, Joaquim, Fay, Andre Poisl, Choueiri, Toni K., Schutz, Fabio Augusto Barros

    Published in Journal of clinical oncology (10-01-2016)
    “…Abstract only 73 Background: Abiraterone and enzalutamide are currently approved for mCRPC patients. Both drugs have distinct mechanisms of action and may have…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20